1. Introduction {#sec1-jpm-10-00003}
===============

Cytochromes P450 (CYP450) drug metabolizing enzymes are the major enzymes in catalyzing the oxidative biotransformation of 70%--80% of all drugs in clinical use to either inactive metabolites or active substances \[[@B1-jpm-10-00003],[@B2-jpm-10-00003]\]. The polymorphism of genes encoding the CYP450 family of enzymes, and in particular CYP2D6 and CYP2C19, has attracted considerable attention as the major targets for pharmacogenomics (PGx) testing since they are highly polymorphic and thereby determining for drug response and adverse drug reactions (ADR) \[[@B3-jpm-10-00003],[@B4-jpm-10-00003],[@B5-jpm-10-00003]\]. The Clinical Pharmacogenetics Implementation Consortium (CPIC) \[[@B6-jpm-10-00003]\] and the Dutch Pharmacogenetics Working Group (DPWG) \[[@B7-jpm-10-00003],[@B8-jpm-10-00003]\] both provide widely recognized clinical dosing guidelines for specific drug-gene interactions (DGI) \[[@B9-jpm-10-00003],[@B10-jpm-10-00003]\]. These are compiled and publically available through the Pharmacogenomics Knowledgebase (PharmGKB; <https://www.pharmgkb.org>) \[[@B11-jpm-10-00003]\]. Based on drug-gene scores for metabolic activity \[[@B12-jpm-10-00003],[@B13-jpm-10-00003],[@B14-jpm-10-00003]\] DGI are classified into five distinct phenotypes defined as; "poor metabolizers" (PM), "intermediate metabolizers" (IM), "extensive metabolizers" (EM; normal activity) and "rapid and ultra-rapid metabolizers" (RM and UM) with UM having faster metabolic activity than RM. We will use the term RM covering both RM and UM throughout this manuscript. The guidelines provide, based on phenotype score, clinical recommendations such as dose adjustment, dose monitoring or avoidance of the given drugs. The FDA also recognizes the importance of DGI and has annotated a large number of drugs with considerations and actions to be taken from a PGx perspective \[[@B11-jpm-10-00003]\].

The term phenoconversion introduces a complicating factor, which potentially can give rise to "genotype-phenotype" mismatches; a person scored as an EM or RM can be phenoconverted to a PM by co-medications \[[@B15-jpm-10-00003]\] (drug--drug interactions). This means that the "true" number of PMs could be significantly higher compared to the number of PMs measured by PGx-testing alone. This term also refers to drug--drug--gene interactions (DDGI) \[[@B16-jpm-10-00003]\]. That phenoconversion could alter a person's drug metabolizing status has been shown in polypharmacy patients \[[@B17-jpm-10-00003],[@B18-jpm-10-00003],[@B19-jpm-10-00003]\] and a recent comprehensive review underscores the importance of assessing and accounting for DGI and DDGI \[[@B4-jpm-10-00003]\]. The guidelines provided by the PharmGKB webpage does not incorporate drug-drug interactions (DDI/DDGI) in the assessment of dose adjustments. However, the issue is recognized and initiatives have been taken to incorporate DDI/DGI in clinical decision tools e.g., youScript^®^ \[[@B19-jpm-10-00003],[@B20-jpm-10-00003]\] which integrates PGx testing with comprehensive drug--gene and drug--drug interaction information to assess the cumulative impact of a patient's genetics and drug regimen, and their risk for adverse drug events. In spite of many initiatives and advances in PGx implementation, significant barriers remain to use PGx-tests proactively; this includes improvement of physician's and pharmacist´s awareness and understanding about PGx as well as convincing evidence presenting the collective clinical utility of a panel of PGx-markers in medication optimization \[[@B21-jpm-10-00003]\]. A Health Technology Assessment report published in 2012 by the Danish Health Authority focusing on the potential use of CYP2D6 and CYP2C19 genotyping as a tool to improve antipsychotic drug treatment concluded that genotyping has the potential. However, the significant organizational hurdles and lack of evidence of PGx-tests utility as a tool for improving the antipsychotic treatment were barriers for daily routine use \[[@B22-jpm-10-00003],[@B23-jpm-10-00003]\].

The aim of this register study was to map the use of drugs in Denmark by applying Anatomical Therapeutic Chemical (ATC) codes \[[@B24-jpm-10-00003]\], for drugs having dosing guidelines (CPIC or DPWG) for CYP2D6 and/or CYP2C19, in terms of consumption of Defined Daily Dose (DDD) \[[@B24-jpm-10-00003]\]. I.e., the assumed average maintenance dose per day for a drug used for its main indication in adults, and number of users who redeemed the drugs during 2017. In addition, consumption of inappropriate drug combinations, according to Medscape^®^ drug interaction checker \[[@B25-jpm-10-00003]\], redeemed to users on the same day or during 2017 are given and discussed in relation to DDI/DDGI. We hope by this study to show the widespread use of drugs having PGx-based clinical dosing guidelines in order to identify areas where PGx testing could be a supporting tool in clinical decision making such as polypharmacy patients. This study present data retrieved from The Danish Register of Medicinal Product Statistics \[[@B26-jpm-10-00003]\].

2. Materials and Methods {#sec2-jpm-10-00003}
========================

2.1. Clinical Dosing Guidelines {#sec2dot1-jpm-10-00003}
-------------------------------

The Clinical Pharmacogenetics Implementation Consortium (CPIC) and the Dutch Pharmacogenetics Working Group (DPWG) clinical dosing guidelines for specific gene-drug pairs were used as the source. The guidelines are available through the publicly available PharmGKB homepage (<https://www.pharmgkb.org/>). By using the PharmGKB website all drugs redeemed in Denmark during 2017, having a CPIC or DPWG guideline for CYP2D6 and/or CYP2C19 drug-gene pairs, were mapped according to their ATC codes \[[@B24-jpm-10-00003]\]. Drugs with guidelines were divided into drugs having an actionable guideline (AG) defined as at least one clinical recommendation (i.e., dose adjustment, dose monitoring, or avoidance of the given drug) different from the EM (normal situation) of any of the phenotypes PM, IM, or RM. Drugs having non-actionable guidelines (N-AG) were defined as drugs with no clinical recommendation different from EM of any of the phenotypes based on current clinical knowledge. N-AG are only provided by DPWG. In depth analyses of consumption were applied within ATC codes N02A (opioids), N05A (antipsychotics), and N06A (antidepressants) due to the relative large number of guidelines existing within these therapeutic groups. Assignment of FDA annotations were gathered from the FDA's "Table of Pharmacogenomic Biomarkers in Drug Labels" for CYP2D6 and CYP2C19 \[[@B11-jpm-10-00003],[@B27-jpm-10-00003]\]. "Actionable PGx" contains information about changes in efficacy, dosage, metabolism, or toxicity due DGI (e.g., "poor metabolizers") relating to these two CYP-enzymes.

2.2. Register Data {#sec2dot2-jpm-10-00003}
------------------

The Danish Register of Medicinal Product Statistics \[[@B26-jpm-10-00003]\], that comprises records of all prescriptions redeemed since 1st of January 1996, were used to retrieve drug consumption in 2017 by using Medstat.dk \[[@B26-jpm-10-00003]\]. Consumption, identifiable with a person, is expressed as defined daily dose (DDD) \[[@B24-jpm-10-00003]\] and number of users who redeemed prescriptions of the drugs searched for as shown in [Table 1](#jpm-10-00003-t001){ref-type="table"}, [Table 2](#jpm-10-00003-t002){ref-type="table"} and [Table 3](#jpm-10-00003-t003){ref-type="table"} and [Figure 1](#jpm-10-00003-f001){ref-type="fig"}. Over the counter (OTC) consumption is not identifiable with a person and therfore is not part of this study. Data given for drug combinations redeemed to the same person, as shown in [Table 4](#jpm-10-00003-t004){ref-type="table"} and [Table 5](#jpm-10-00003-t005){ref-type="table"}, were retrieved by using the personal identification number \[[@B28-jpm-10-00003]\] (the CPR number), a unique identifier to all Danish inhabitants since 1968, to link the number of users who redeemed the combination of drugs shown on the same day or during 2017. In addition, [Table 5](#jpm-10-00003-t005){ref-type="table"} also present data on age distribution of comsumption. These data are not publically available and were provided from the same register as above by Statistics Denmark \[[@B29-jpm-10-00003]\] upon request. This also explains the minor differences seen in numbers in [Table 4](#jpm-10-00003-t004){ref-type="table"} compared to [Table 1](#jpm-10-00003-t001){ref-type="table"}, [Table 2](#jpm-10-00003-t002){ref-type="table"} and [Table 3](#jpm-10-00003-t003){ref-type="table"}. Data provided by Statistic Denmark were retrieved at another time compared to [Table 1](#jpm-10-00003-t001){ref-type="table"}, [Table 2](#jpm-10-00003-t002){ref-type="table"} and [Table 3](#jpm-10-00003-t003){ref-type="table"} and thereby small adjustments of data have occurred. For conversion to prevalence (users/1000 inhabitants), the total Danish population in 2017 was 5.748.769 (<https://www.statistikbanken.dk/statbank5a/default.asp?w=1920>). Drug-drug interactions were scored in severity by using Medscape^®^ drug interaction checker \[[@B25-jpm-10-00003]\] and warnings related to CYP2D6 and/or CYP2C19 are displayed as "monitor closely" or "serious use alternate". The dosing information, length of treatment and indication for prescribing were not recorded and ethics approval was not applicable according to Danish law, since the use of anonymized healthcare data for pharmacoepidemiological research does not require subject consent or approval from the Ethics Committee.

3. Results {#sec3-jpm-10-00003}
==========

In 2017 in Denmark 49 drugs corresponding to 469.1 million DDD had CPIC/DPWG guidelines (both AG and N-AG) for CYP2D6 and/or CYP2C19 drug gene pair's equivalent to 14.5% of the total sale in DDD. Of these, 28 drugs have AG corresponding to 375.2 million DDD i.e., 80.0% of total consumption in DDD of drugs having both AG and N-AG. Fifty-eight percent of the consumption in DDD of drugs having AG was within the ATC codes of A02BC (proton pump inhibitors--- pantoprazole (61.3 million DDD, 312,000 users), lansoprazole (33.6 million DDD, 146,000 users), and omeprazole (37.1 million DDD, 130,480 users)); B01AC (platelet aggregation inhibitors excluding heparin---clopidogrel (36.8 million DDD, 120,000 users)); and C07AB (beta blocking agents--- metoprolol (47.7 million DDD, 277,660 users)).

Most of the guidelines in terms of number, both AG and N-AG, exist within the ATC codes N06A (antidepressants drugs), N02A (opioids) including codeine (R05DA04), and N05A (antipsychotic drugs). Due to this, the consumption of drugs within these ATC codes in DDD and number of users who redeemed the drugs were further scrutinized. The total consumption in 2017 were 157.0, 48.9, and 23.7 million DDD for antidepressants, opioids, and antipsychotics, respectively ([Figure 1](#jpm-10-00003-f001){ref-type="fig"}A--C). The consumption of drugs having AG constituted 78.6% and 57.5% of the total consumption in DDD for antidepressants and opioids, which corresponds to the consumption of 11 and 3 different drugs, respectively (see also [Table 1](#jpm-10-00003-t001){ref-type="table"} and [Table 2](#jpm-10-00003-t002){ref-type="table"}). The same numbers for antipsychotic drugs were 17.6% for the consumption of four drugs.

[Table 1](#jpm-10-00003-t001){ref-type="table"}, [Table 2](#jpm-10-00003-t002){ref-type="table"} and [Table 3](#jpm-10-00003-t003){ref-type="table"} show the total consumption in DDD of antidepressants, opioids, and antipsychotics in increasing order as well as number of users who redeemed the drugs. Note that the numbers of users for the different drugs shown are not additive, since dispensing to the same users can occur for the different drugs. The Tables also give an overview of drugs having both actionable-, non-actionable- and no-guidelines at all, as well as drugs having FDA approved annotations in their drug labels containing PGx information for CYP2D6 and CYP2C19 drug--gene pairs. Moreover, drugs known to be inhibitors of CYP2D6 or CYP2C19 \[[@B30-jpm-10-00003]\] are also marked. For antidepressants sertraline, citalopram, and venlafaxine ([Table 1](#jpm-10-00003-t001){ref-type="table"}) both in terms of DDD and number of users were the most redeemed drugs. The consumption of these three drugs constituted approximately 50% of total consumption of DDD in this drug class and they all have AG and, for citalopram and venlafaxine, FDA annotations as well.

For analgesics ([Table 2](#jpm-10-00003-t002){ref-type="table"}), the consumption of opioids including codeine in DDD constituted 24.8% of the total consumption of analgesics. Both tramadol and codeine have AG and FDA annotations and the consumption of these drugs in both DDD and number of users constituted more than 50% of total consumption of opioids. Since the content of codeine in N2AJ06 equals that of codeine (R05DA04) i.e., 25 mg, opposite N02AJ07 where the content is three times less, the notion AG and FDA annotation was added to this combination of codeine and paracetamol.

In case of antipsychotic drugs ([Table 3](#jpm-10-00003-t003){ref-type="table"}) the total consumption in DDD and users is somewhat less compared to opioids and antidepressants and only four drugs out of 24 drugs have AG ([Table 3](#jpm-10-00003-t003){ref-type="table"} shows 16 drugs. See legend to Table), however, the highest prevalence of non-AG exists within this drug class. Additionally, in this class of drugs, the annotation "test required" is seen for pimozide. Ariprazole is the most selling drug having both and AG and FDA annotation. For most, but not all, of the drugs shown in the tables there is a good match between those having AG and FDA annotations.

[Table 4](#jpm-10-00003-t004){ref-type="table"} shows the number of users who redeemed on the same day or during 2017, a combination of drugs (antidepressants) known as inhibitors of CYP2D6 \[[@B30-jpm-10-00003]\] together with either codeine, tramadol, metoprolol, or amitriptyline. All drugs in the table have AG. From the table it can be seen that e.g., 264,065 users redeemed tramadol, 30,405 users redeemed duloxetine, and 5,544 users redeemed the combination of tramadol and duloxetine during 2017, and 2,126 redeemed the combination on the same day. It can be calculated from the table that users who redeemed the combinations of drugs on the same day as percentage of the whole year ranged from 27.8% for the combination of sertraline and codeine to 63.3% for paroxetine and metoprolol with a median value of 41.7%. The highest prevalence's for combinations were seen for sertraline in combination with tramadol or metoprolol for both the same day and the whole year. By using the drug interaction tracker provided by Medscape \[[@B25-jpm-10-00003]\] the aim was to visualize warnings "monitor closely" and "serious use alternate" for different drug combinations shown. Most of the drug combinations in the [Table 4](#jpm-10-00003-t004){ref-type="table"} were scored by the tracker as either "monitor closely" or "serious use alternate" in relation to CYP2D6.

[Table 5](#jpm-10-00003-t005){ref-type="table"} shows age-distribution expressed as prevalence of users who redeemed tramadol, metoprolol and sertraline either alone or in combination during 2017. The prevalence of tramadol and metoprolol redeemed alone or in combination with sertraline ((S + T) and (S + M)) increased as function of increasing age intervals with the highest prevalence seen for 80+ years. The prevalence of sertraline varies around 18--22 for most age intervals with the highest prevalence seen for 80+ years. The Table also shows (right part) the prevalence of sertraline in combination with tramadol (S + T) or in combination with metoprolol (S + M) expressed relative to the prevalence of sertraline, tramadol and metoprolol. As seen, the relative prevalence of S + T and S + M when expressed relative to sertraline increases as function of age intervals, whereas the relative prevalence of S + T and S + M relative to tramadol and metoprolol did not vary much across age intervals.

4. Discussion {#sec4-jpm-10-00003}
=============

This study visualizes the drug consumption in Denmark in 2017 for drugs having CPIC and/or DPWG dosing guidelines and FDA annotations and suggests future directions, especially with focus on vulnerable polypharmacy patients. Pharmacogenomics based prescribing is one of the first applications of genomics in medicine \[[@B21-jpm-10-00003]\] and testing of polymorphism of genes encoding CYP450 enzymes and in particular CYP2D6 and CYP2C19, but also CYP2C9 has the potential to be a valuable tool to optimize prescribing, dosing, and monitoring by identifying phenotype status \[[@B17-jpm-10-00003],[@B18-jpm-10-00003],[@B19-jpm-10-00003],[@B31-jpm-10-00003]\] and to reduce re-hospitalization in polypharmacy patients \[[@B32-jpm-10-00003]\]. However, significant barriers still exist mainly concerning physicians´ and pharmacists´ awareness and education, and question marks about evidence levels and significance are brought into the discussions. In Denmark the situation does not look much different and the use of PGx tests have not gained foothold in daily clinical practice \[[@B22-jpm-10-00003]\] mainly because of significant organizational barriers and lack of evidence. It has been estimated that around 750,000 Danes are polypharmacy users defined as taking ≥5 drugs corresponding to 13% of the Danish population and for 75+ years, 54% of this age group are polypharmacy users \[[@B32-jpm-10-00003]\]. Taken the average Caucasian frequencies of DGI recently reported \[[@B31-jpm-10-00003]\] for CYP2D6 (UM 4.1%, IM 6.2%, and PM 5.4%) and for CYP2C19 (UM 31.5%, 26.9%, and PM 2.6%) into consideration further suggests that a significant proportion of the Danish population will have phenotypes for which actions in principle should be taken regarding dose adjustments or avoidance of the given drugs. By using the above numbers, which are in alignment with other reported prevalence's \[[@B33-jpm-10-00003]\], it can roughly be estimated that approximately 0.9 million of the total Danish population of 575 million will be either UM, IM, or PM for CYP2D6 and approximately 3.5 million for CYP2C19, and for polypharmacy users the numbers are approximately 0.1 and 0.5 million, respectively, of which the elderly constitutes 50% (see above). Medication reviews performed in two Danish nursing homes, of which all residents were polypharmacy users, revealed that 80% of the residents were administered drugs for which there exists AG (unpublished results). This underscores the findings of this study showing that a large portion of the Danish population, in particular the elderly, has been or will be exposed to one or more drugs having AG. Citalopram, clopidogrel, lansoprazole, omeprazole, pantoprazole, and sertraline were each redeemed to more than 100,000 users, and metoprolol and tramadol to more than 250,000 users. For example, the dosing guidelines for tramadol (<https://www.pharmgkb.org>) alert to an action to be taken for CYP2D6 IM, PM, or UM metabolizers, and based on the above frequencies for UM, IM, and PM for CYP2D6 approximately 41,000 of the 265,030 users who redeemed tramadol could potentially be considered for an action to be taken.

In spite of that a large number of antipsychotic drug are metabolized by CYP2D6 and CYP2C19, only a very few have AG and FDA annotations, with aripiprazol as the most redeemed (11,900 users) drug with an AG. However, due to the complexity of dosing antipsychotic drugs several dosing models based on PGx testing (among others) have been proposed \[[@B34-jpm-10-00003],[@B35-jpm-10-00003]\].

The publically available drug-interaction checker provided by MedScape, used in this study to score for severity of DDI, showed that for the drug combinations investigated, mostly all had warnings related to inhibition of CYP2D6 activity by duloxetine, fluoxetine, paroxetine, and sertraline. The number of users affected by the warning "serious use alternate" seem to be relatively low compared to the number of user affected by the warning "monitor closely". Surprisingly, the fraction of drug users who redeemed the drug combinations investigated for on the same day seem to be relative high (median value of 41.7%) compared to the whole year. Personal experiences from the pharmacy practice is, that the warning "monitor closely" is very seldom taken into consideration unless the user has undergone a medication review. The warning "serious use alternate", if caught, is in principle simpler to handle due to the clear message of action. However, independently of the drug combinations are redeemed on the same day or during the same year, actions can only be taken if it is brought to the attention of the pharmacist and physician. This study does not provide data on how many unwanted drug combinations that have been captured during the dispensing process. If the impact of being scored as PM or UM is also taken into consideration, the balance between "monitor closely" and "serious use alternate" might change significantly towards the latter, which recently has been substantiated for opioids \[[@B17-jpm-10-00003],[@B36-jpm-10-00003]\] and for metoprolol \[[@B37-jpm-10-00003]\]. It should be mentioned that other drug-interaction checkers might score the warnings shown in [Table 5](#jpm-10-00003-t005){ref-type="table"} differently from that obtained in this study, e.g., "Interaktionsdatabasen" provided by the Danish Medicines Agency (<http://www.interaktionsdatabasen.dk/)>; however, it is the author's opinion that the principles outlined above still will be valid.

The increased prevalence's of tramadol and metoprolol redeemed alone or in combination with sertraline as function of age intervals seen in this study support the notion that elderly people are more exposed to inappropriate polypharmacy than younger people are \[[@B38-jpm-10-00003]\]. The term "used or redeemed alone" in this study does not exclude that users could have redeemed other drug combinations not looked for. The prevalence's of sertraline in combination with tramadol (S + T) or in combination with metoprolol (S + M) expressed relative to the prevalence of sertraline, tramadol, and metoprolol alone ([Table 5](#jpm-10-00003-t005){ref-type="table"}) suggests that the fraction of sertraline users who get tramadol or metoprolol increases as a function of age. The opposite is found when expressed as relative to the prevalence of tramadol or metoprolol, as the fraction of metoprolol and tramadol users getting sertraline is constant across age intervals. The same pattern was seen for duloxetine in combination with tramadol and metoprolol (results not shown). In conclusion, the limitations of this register study are that the numbers of users who redeemed the drugs searched for in this publication does not provide any information about dose, compliance, and clinical effects, as well as duration of treatments. However, the findings of this exploratory register study clearly showed that a large fraction of the Danish population, especially the elderly part, are exposed to drugs or drug combinations for which there exist dosing guidelines provided by CPIC or DPWG as well as FDA annotation related to PGx of CYP2D6 and CYP2C19. This underscores the importance of accessing and accounting for DDI, DGI, and DDGI, focusing on the elderly vulnerably (e.g., those in nursing homes) in the first place, while understanding that it is a complex process demanding multidisciplinary collaborations to obtain infrastructural capacities for good decision-making processes, as well as further studies to assess the economic impact of pre-emptive PGx-panel testing.
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jpm-10-00003-t001_Table 1

###### 

Consumption of antidepressants.

  Antidepressants         ATC-Code   CYP2D6   CYP2C19   FDA Ann.   Consumption (Users)   Consumption (DDD) (×1000)
  ----------------------- ---------- -------- --------- ---------- --------------------- ---------------------------
  Total antidepressants   N06A                                     414,850               156,968
  Sertraline ^1^          N06AB06    \-       AG        \-         100,925               43,690 (27.8)
  Citalopram              N06AB04    \-       AG        A          100,125               34,554 (22.0)
  Venlafaxine             N06AX16    AG       \-        A          50,155                22,757 (14.5)
  Mirtazapine             N06AX11    NG       NG        \-         82,300                15,637 (10.0)
  Escitalopram            N06AB10    \-       AG        A          24,020                9259 (5.9)
  Duloxetine ^1^          N06AX21    NG       \-        A          30,500                8613 (5.4)
  Paroxetine ^1^          N06AB05    AG       \-        I          12,935                4960 (3.1)
  Fluoxetine ^1,2^        N06AB03    NG       NG        I          10,815                4207 (2.7)
  Amitriptyline           N06AA09    AG       AG        A          35,020                3625 (2.3)
  Nortriptyline           N06AA10    AG                 A          14,965                3222 (2.1)
  Agomelatine             N06AX22    \-       \-                   5370                  1827 (1.1)
  Vortioxetine            N06AX26    \-       \-        A          5700                  1601 (1.0)
  Mianserin               N06AX03    \-       \-        \-         12,070                1081 (\<1)
  Clomipramine ^1^        N06AA04    AG       AG        A          2775                  745 (\<1)
  Imipramine              N06AA02    AG       AG        A          4085                  441 (\<1)
  Isocarboxazid           N06AF01    \-       \-        \-         380                   227 (\<1)
  Bupropion ^1^           N06AX12    \-       \-        \-         2005                  149 (\<1)
  Doxepin ^1^             N06AA12    AG       AG        A          485                   99 (\<1)
  Dosulepin               N06AA16    \-       \-        \-         405                   92 (\<1)
  Reboxetine              N06AX18    \-       \-                   375                   79 (\<1)
  Fluvoxamine ^2^         N06AB08    AG       \-        A          185                   57 (\<1)
  Moclobemide             N06AG02    \-       NG        \-         120                   44 (\<1)
  Maprotiline             N06AA21    \-       \-        \-         20                    3 (\<1)

The table is sorted in order of increasing consumption. AG: actionable guideline, N-AG: non-actionable guideline, and -: no guideline. FDA annotation (FDA ann.) related to CYP2D6 and/or CYP2C19. Numbers in brackets are percentage expressed relative to the total consumption of antidepressants in DDD: A = action, I = informative; T-req = test required. DDD: Defined Daily Dose (DDD). ^1^ Inhibitor of CYP2D6 and ^2^ inhibitor CYP2C19 \[[@B30-jpm-10-00003]\].

jpm-10-00003-t002_Table 2

###### 

Consumption of analgesics.

  ----------------------------------------------------------------------------------------------------------------------------
  Analgesics                        ATC Code   CYP2D6   CYP2C19   FDA Ann.   Consumption (Users)   Consumption (DDD) (×1000)
  --------------------------------- ---------- -------- --------- ---------- --------------------- ---------------------------
  Total analgesics                  N02                                      1,231,305             196,593

  Total opioids                     N02A                                     427,765               44,508\
                                                                                                   48,875 \* (24.8)

  Tramadol                          N02AX02    AG                 A          265,030               20,520 (42.0)

  Morphine                          N02AA01                                  97,765                5698 (11.7)

  Codeine & acetylsalicylic acid)   N02AJ07                                  20,980                5536 (11.3)

  Oxycodone                         N02AA05    NG                            69,470                4416 (9.0)

  Codeine \*                        R05DA04    AG                 A          71,135                4367 (8.9)

  Codeine & paracetamol \*\*        N02AJ06    (AG)               \(A\)      24,210                3209 (6.6)

  Fentanyl                          N02AB03                                  18,815                3046 (6.2)

  Buprenorphine                     N02AE01                                  17,470                1132 (2.3)

  Ketobemidone and antispasmodics   N02AG02                                  6085                  419 (\<1)

  Tapentadol                        N02AX06                                  2110                  302 (\<1)

  Hydromorphone                     N02AA03                                  85                    124 (\<1)
  ----------------------------------------------------------------------------------------------------------------------------

See [Table 1](#jpm-10-00003-t001){ref-type="table"} for legend. \* Codeine (R05DA04) is included in the total consumption of opioids in DDD (44,508 + 4367 = 48,875 (1000)). Numbers in brackets are percentage expressed relative to total consumption of opioids incl. codeine in DDD. \*\* Since codeine is approximately 25 mg in N02AJ06, opposite N02AJ07 where the content is three times less, the term AG was applied. Drugs or drug combinations with a consumption of less of 100,000 DDD are not shown.

jpm-10-00003-t003_Table 3

###### 

Consumption of antipsychotics.

  Antipsychotics         ATC Code   CYP2D6   CYP2C19   FDA Ann.   Consumption (Users)   Consumption (DDD) (×1000)
  ---------------------- ---------- -------- --------- ---------- --------------------- ---------------------------
  Total antipsychotics   N05A                                     128,935               23,705
  Quetiapine             N05AH04    NG       \-        \-         61,665                5991 (25.3)
  Olanzapine             N05AH03    NG       \-        \-         17,335                5389 (22.7)
  Aripiprazole ^1^       N05AX12    AG       \-        A          11,900                2711 (11.7)
  Lithium                N05AN01    \-       \-        \-         8925                  2175 (9.2)
  Risperidone            N05AX08    NG       \-        I          16,080                1931 (8.1)
  Clozapine              N05AH02    NG       \-        A          3375                  1118 (4.7)
  Zuclopenthixol         N05AF05    AG       \-        \-         4475                  815 (3.4)
  Chlorprothixene        N05AF03    \-       \-        \-         15,785                689 (2.9)
  Paliperidone           N05AX13    \-       \-        \-         1490                  587 (2.5)
  Haloperidol ^1^        N05AD01    AG       \-        \-         6290                  532 (2.2)
  Ziprasidone            N05AE04    \-       \-        \-         1145                  474 (2.0)
  Flupenthixol           N05AF01    NG       \-        \-         4305                  308 (1.3)
  Perphenazine           N05AB03    \-       \-        \-         575                   270 (1.1)
  Amisulpride            N05AL05    \-       \-        \-         740                   189 (\<1)
  Levomepromazine        N05AA02    \-       \-        \-         4605                  136 (\<1)
  Pimozide               N05AG02    AG       \-        T-req      615                   110 (\<1)

See [Table 1](#jpm-10-00003-t001){ref-type="table"} for legend. Numbers in brackets are percentage expressed relative to total consumption of antipsychotics in DDD. T-req = test required and I = informative. Drugs with a consumption of less of 100,000 DDD are not shown.
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###### 

Consumption of drug combinations having Clinical Pharmacogenetics Implementation Consortium CPIC/Dutch Pharmacogenetics Working Group (DPWG) dosing guidelines.

                             Codeine                 Tramadol               Metoprolol           Amitriptyline
  ---------------- --------- ----------------------- ---------------------- -------------------- -------------------
                             70,853                  264,065                277,090              34,922
  Duloxetine ^1^   30,405    [1153 (355)]{.ul}       **5544 (2126)**        [2596 (1399)]{.ul}   **1825 \* (592)**
  Fluoxetine ^1^   10,733    [347/0.06 (127)]{.ul}   [1102 \* (443)]{.ul}   **699 (409)**        **158 (77)**
  Paroxetine ^1^   12,881    [341/0.06 (108)]{.ul}   [1202 (441)]{.ul}      **1203 (761)**       **183 \* (82)**
  Sertraline ^1^   100,490   [2644 (734)]{.ul}       [11,221 (3962)]{.ul}   [8014 (4156)]{.ul}   **1496 \* (582)**

Data are presented as total no of users who redeemed the drugs shown either alone (upper and left panel) or in combination during 2017. Numbers in brackets show total number of users who redeemed the drug combinations on the same day. ^1^ Inhibitor of CYP2D6. Drug--drug interactions are scored by using MedScape \[[@B25-jpm-10-00003]\]. Underlined: monitor closely; bold: serious use alternate. All warnings are related to CYP2D6 activity except \*. This warning refers to increases in serotonin levels.
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###### 

Age distribution of consumption in terms of prevalence.

           Sertraline   Tramadol   Metoprolol   (S + T)   (S + M)   (S + T)/S   (S + T)/T   (S + M)/S   (S + M)/M
  -------- ------------ ---------- ------------ --------- --------- ----------- ----------- ----------- -----------
  00--19   4.0          2.3        0.6          0.1       0.0       1.3         2.3         0.4         2.3
  20--29   20.2         18.9       2.3          0.9       0.1       4.5         4.8         0.7         6.1
  30--39   23.1         34.1       5.4          1.8       0.3       7.6         5.2         1.4         5.7
  40--49   22.3         49.8       18.3         2.4       0.8       10.7        4.8         3.8         4.6
  50--59   19.5         62.9       47.7         2.6       1.5       13.3        4.1         7.8         3.2
  60--69   18.2         76.4       106.4        2.8       2.7       15.5        3.7         14.6        2.5
  70--79   20.6         92.5       161.9        3.7       4.0       18.0        4.0         19.6        2.5
  80--     29.3         117.2      205.5        5.1       6.4       17.4        4.3         21.9        3.1
  All      17.5         45.9       48.2         2.0       1.4       11.2        4.2         8.0         2.9

Left part of the Table: Age distribution of consumption expressed in terms of prevalence. (S + T): sertraline redeemed in combination with tramadol; (S + M): sertraline redeemed in combination with metoprolol. "All" is the prevalence across all age groups (bottom row). Right part of the table: prevalence in percentage of (S + T) and (S + M) relative to (S) sertraline, (T) tramadol and (M) metoprolol.
